menu search

BHVN / Biohaven Pharmaceutical: Recent Growth Will Continue

Biohaven Pharmaceutical: Recent Growth Will Continue
Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks. Read More
Posted: Apr 14 2022, 04:23
Author Name: Seeking Alpha
Views: 103178

BHVN News  

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

By Zacks Investment Research
October 31, 2023

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year. more_horizontal

Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going

By Zacks Investment Research
October 19, 2023

Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going

Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. more_horizontal

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

By Zacks Investment Research
September 28, 2023

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases. more_horizontal

Why Biohaven Stock Is Skyrocketing Today

By The Motley Fool
September 27, 2023

Why Biohaven Stock Is Skyrocketing Today

Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promis more_horizontal

Why Biohaven Stock Is Crashing Today

By The Motley Fool
July 27, 2023

Why Biohaven Stock Is Crashing Today

The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency more_horizontal

Why Biohaven Stock Caught Fire This Week

By The Motley Fool
June 2, 2023

Why Biohaven Stock Caught Fire This Week

Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appe more_horizontal

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

By Zacks Investment Research
March 23, 2023

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders. more_horizontal

Biohaven: Spun And Done - Time To Exit

By Seeking Alpha
March 9, 2023

Biohaven: Spun And Done - Time To Exit

Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either e more_horizontal


Search within

Pages Search Results: